Sean Laaman
Stock Analyst at Morgan Stanley
(2.46)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
EXEL Exelixis | Maintains: Overweight | 48 46 | 37.43 | 22.9% | 1 | Jul 29, 2025 | |
AXSM Axsome Therapeutics | Assumes: Overweight | 190 | 103.95 | 82.78% | 1 | Jul 3, 2025 | |
IRON Disc Medicine | Assumes: Overweight | 85 | 58.61 | 45.03% | 1 | Jul 3, 2025 | |
CERT Certara | Assumes: Equal-Weight | 16 | 10.46 | 52.96% | 1 | Jul 3, 2025 | |
ONC BeOne Medicines | Maintains: Overweight | 313 330 | 289.69 | 13.91% | 1 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Underweight | 3 2 | 2.24 | -33.04% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 300 | 184.71 | 62.42% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 169 | 284.43 | -40.58% | 1 | Oct 27, 2023 |